About

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Lupus patients given hope of remission in groundbreaking trial

Microscope

UCB and Biogen announce positive Phase 3 results of dapirolizumab pegol in SLE from the PHOENYCS GO study

Lupus Therapy Essentials 2024 Update

World Kidney Day 2024

Nature Logo

Researchers from Trinity College Dublin establish a link between fumarate hydratase and inflammatory macrophages, identifying a potential future treatment pathway for lupus.

Publication thumbnail: Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation

Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation

Publication thumbnail: Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial

Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial

Publication thumbnail: Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study

Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study

Publication thumbnail: Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first-in-patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first-in-patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

Publication thumbnail: CD19-CAR T-cell therapy induces deep tissue depletion of B cells

CD19-CAR T-cell therapy induces deep tissue depletion of B cells

Publication thumbnail: Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus:  A Phase 2 randomized controlled trial

Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial

Publication thumbnail: Urinary soluble CD163 is useful as "liquid biopsy" marker in  lupus nephritis at both diagnosis and follow-up to predict  impending flares

Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares

Publication thumbnail: Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes

Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes

Publication thumbnail: Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study

Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study

Publication thumbnail: Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Publication thumbnail: Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis

Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis

Publication thumbnail: Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement

Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement

Publication thumbnail: ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials

ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials

Publication thumbnail: Belimumab Corticosteroid‑Sparing Treatment in Systemic Lupus Erythematosus: a Real‑Life Observational Study (BESST)

Belimumab Corticosteroid‑Sparing Treatment in Systemic Lupus Erythematosus: a Real‑Life Observational Study (BESST)

Publication thumbnail: SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

Publication thumbnail: Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two Phase 3 trials

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two Phase 3 trials

Publication thumbnail: TYK2: An emerging therapeutic target in rheumatic disease

TYK2: An emerging therapeutic target in rheumatic disease

Publication thumbnail: Cardiovascular risk factors and complications in patients with  systemic lupus erythematosus with and without nephritis: A systematic review and meta-analysis

Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: A systematic review and meta-analysis

Publication thumbnail: Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: A multinational observational cohort study

Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: A multinational observational cohort study

Publication thumbnail: Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: A cohort study with up to 11 years of follow-up

Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: A cohort study with up to 11 years of follow-up

Publication thumbnail: CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up

CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up

Publication thumbnail: Evaluation of RNase Therapy in Systemic Lupus Erythematosus:  A Randomised Phase 2a Clinical Trial of RSLV-132

Evaluation of RNase Therapy in Systemic Lupus Erythematosus: A Randomised Phase 2a Clinical Trial of RSLV-132

Publication thumbnail: Smith-specific regulatory T cells halt the progression of lupus nephritis

Smith-specific regulatory T cells halt the progression of lupus nephritis

Publication thumbnail: Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: A multicentre, open-label, randomised controlled trial

Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: A multicentre, open-label, randomised controlled trial

Publication thumbnail: Development of the American College of Rheumatology's  Patient-reported Outcome Quality Measures for Systemic Lupus Erythematosus

Development of the American College of Rheumatology's Patient-reported Outcome Quality Measures for Systemic Lupus Erythematosus

Publication thumbnail: Predictors of Renal Flares in Systemic Lupus Erythematosus: A Post-hoc Analysis of Four Phase III Clinical Trials of Belimumab

Predictors of Renal Flares in Systemic Lupus Erythematosus: A Post-hoc Analysis of Four Phase III Clinical Trials of Belimumab